Evidence map›Paper›PMID 37312093›Full record

ArticleVirology journal2023

Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman.

L Di Girolamo, M Ferrara, G Trevisan, B M Longo, T Allice, E Burdino, F Alladio, S Fantino, G Di Perri, A Calcagno and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Virology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

L Di Girolamo *Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
M Ferrara *Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy. micol.ferrara29@gmail.com.
G TrevisanUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
B M LongoUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
T AlliceLaboratory of Microbiology and Virology, Amedeo di Savoia Hospital ASL Città di Torino, Turin, Italy.
E BurdinoLaboratory of Microbiology and Virology, Amedeo di Savoia Hospital ASL Città di Torino, Turin, Italy.
F AlladioUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
S FantinoUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
G Di PerriUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
A CalcagnoUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
S BonoraUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
University of Turin · ITOspedale Amedeo di Savoia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElite controllers are able to control viral replication without antiretroviral therapy. Exceptional elite controllers do not show disease progression for more than 25 years. Different mechanisms have been proposed and several elements of both innate and adaptive immunity are implicated. Vaccines are immune stimulating agents that can promote HIV-RNA transcription; transient plasma HIV-RNA detectability has been described within 7-14 days after different vaccinations. The most reliable mechanism involved in virosuppressed people living with HIV is a generalized inflammatory response that activates bystander cells harboring latent HIV. So far no data about viral load increase in elite controllers after SARS-CoV-2 vaccination are reported in literature. CASE PRESENTATION: We report the case of a 65-year-old woman of European ancestry, diagnosed with HIV-1/HCV co-infection more than 25 years ago. Since then, HIV-RNA remained undetectable and she never received ARV therapy. In 2021 she was vaccinated with mRNA-BNT162b2 vaccine (Pfizer-BioNTech®). She was administered with three doses in June, July and October 2021, respectively. The last available viral load was undetectable in March 2021. We observed an increase of VL at 32 cp/ml and 124 cp/mL, two and seven months after the second vaccine dose, respectively. During monthly follow-up, HIV-RNA gradually and spontaneously dropped becoming undetectable without ARV intervention. COVID-19 serology was positive with IgG 535 BAU/mL, showing response to vaccination. We measured total HIV-DNA at different time-points and we found it detectable both at the time of the higher plasma HIV-RNA (30 cp/10^6 PBMCs) and when it was undetectable (13 cp/10^6 PBMCs), in reduction.

conclusionsThis case is the first report, to our knowledge, describing a rebound of plasma HIV-RNA in an elite controller after three doses of mRNA-BNT162b2 vaccine for SARS-CoV-2. Concomitantly with a spontaneous reduction of plasma HIV-RNA ten months after the third dose of mRNA-BNT162b2 vaccine (Pfizer-BioNTech®) without antiretroviral therapy intervention, we observed a reduction of total HIV-DNA in peripheral mononuclear cells. The potential role of vaccinations in altering HIV reservoir, even in elite controllers when plasma HIV-RNA is undetectable, could be a valuable aspect to take into account for the future HIV eradication interventions.

Indexed as

COVID-19HIV-1HIV InfectionsHIV SeropositivityAgedBNT162 VaccineCOVID-19 VaccinesElite ControllersFemaleHumansRNA, MessengerSARS-CoV-2VaccinationVirus LatencyBNT162 VaccineCOVID-19 VaccinesRNA, MessengerElite controllerHIVHIV-RNA reboundSARS-CoV-2 mRNA vaccinesTotal HIV-DNA

Identifiers

PMID37312093
PMCPMC10262927
OpenAlexW4380480779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.